About Medlink Therapeutics:
Founded in July 2020, Medilink Therapeutics is at the forefront of innovative drug development, specializing in antibody-drug conjugates (ADCs) and advanced technologies. Medilink’s proprietary Tumor Microenvironment Activable Linker-payload (TMALIN®) platform enhances ADC drug stability and therapeutic effectiveness, providing groundbreaking treatment options for cancer patients worldwide.
Challenges in Digital Transformation
With a strong focus on digital transformation, Medilink’s R&D teams were already familiar with electronic notebooks for data recording. However, to maximize efficiency and minimize risks associated with delayed technology adoption, Medilink sought to implement a comprehensive Electronic Lab Notebook (ELN) system swiftly. The goal was to create a fully digital R&D workflow to streamline data acquisition, analysis, and management, reduce costs, and optimize the use of historical data.
Neotrident’s Digital Solutions: iLabPower PM, ELN, and RegMS
In 2021, Medilink collaborated with Neotrident Technology to integrate iLabPower Project Management (PM) system, Electronic Lab Notebook (ELN), and Compound Management System (RegMS). These systems transformed Medilink’s R&D management by enabling efficient project planning, real-time task allocation, and structured experimental data recording. The iLabPower PM system provided robust project oversight, ELN facilitated detailed experiment documentation, and RegMS streamlined compound registration, synthesis route management, and biotest data handling.
The integration of these digital tools established a cohesive, data-driven model for tracking, storing, and analyzing experimental and project data, significantly enhancing R&D productivity.
Advanced Data Integration with Scientific Data Hierarchy (SDH)
In 2024, Medilink further expanded its digital capabilities by deploying Neotrident’s Scientific Data Hierarchy (SDH) platform. SDH integrates and analyzes data from ELN, spreadsheets, and other sources, elevating Medilink’s data analysis efficiency and supporting informed decision-making in ADC development.
Key Results & Benefits
- Boosted Experimental Output: Implementation of the iLabPower ELN system increased each scientist’s daily experiments from under 10 to 14-15, achieving a nearly 900% ROI.
- Industry Recognition: Medilink’s data-driven R&D platform, developed with Neotrident, was recognized as part of the “2023 Suzhou Artificial Intelligence Application Scenario Demonstration Project,” reinforcing its leadership in drug discovery.
- Enhanced Compliance and Trust: iLabPower ELN ensured data integrity and compliance, helping Medilink successfully pass audits, gain regulatory approval, and build stronger client relationships.
Driving Innovation in ADC Drug Development
With the powerful integration of iLabPower PM, ELN, and SDH, Medilink Therapeutics continues to advance its R&D processes, setting new standards in ADC drug development. The digital solutions provided by Neotrident empower Medilink to maintain compliance, enhance efficiency, and foster innovation, positioning the company at the cutting edge of biopharmaceutical research.
